Mithera Capital

Mithera Capital is a clinical-stage biotechnology company and investment firm focused on developing innovative therapies for cardiovascular diseases and oncology-related complications. The company's lead candidate, MTH-001 (formerly GGF2), is a recombinant human Neuregulin-1 protein acquired from Acorda Therapeutics and is currently in Phase 2 development for the prevention of anthracycline-induced cardiotoxicity in cancer patients. Additionally, Mithera is advancing a gene therapy platform, including AAV-NRG1, aimed at treating chronic heart failure by promoting myocardial regeneration. The firm utilizes a strategic investment model to acquire and accelerate the development of high-potential clinical assets that address significant unmet medical needs. Headquartered in New York, Mithera Capital is led by a management team with deep expertise in life science finance and drug development.